You are viewing: South Korea Veterinary Pharmaceuticals Market analysis

The South Korea Veterinary Pharmaceuticals Market was valued at $314.6 Million in 2026 and projected to reach to $444.1 Million by 2031, representing a compound annual growth rate of 7.1%. South Korea's veterinary pharmaceuticals market is positioned for sustained growth through 2031, driven by evolving consumer attitudes toward pet healthcare and stringent livestock management standards.

South Korea Veterinary Pharmaceuticals Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Veterinary Pharmaceuticals Market Trends and Insights

  • This represents a compound annual growth rate (CAGR) of 7.1%, outpacing global market expansion.
  • South Korea's advanced healthcare infrastructure, rising pet ownership, and increasing livestock disease management investments are driving demand for innovative veterinary pharmaceutical solutions. The South Korea market benefits from strong regulatory frameworks and high consumer spending on animal health.
  • South Korea's growing aquaculture and poultry sectors are particularly significant contributors to pharmaceutical consumption.
  • Between 2026 and 2031, South Korea is expected to see accelerated adoption of preventive care products and biologics, supported by government initiatives promoting animal welfare standards and food safety protocols..

Key Market Statistics

  • CAGR (2026-2031) 7.1% CAGR
  • Market Size, 2026 ~USD 314.6 Million
  • Forecast, 2031 ~USD 444.1 Million
  • Country South Korea

South Korea Veterinary Pharmaceuticals Market Overview

Market Valuation Growth :

South Korea's veterinary pharmaceuticals market is valued at USD 314.6 million in 2026, with projections reaching USD 444.1 million by 2031, demonstrating strong market expansion potential.

Outpacing Global Growth :

At 7.1% CAGR, South Korea's market growth significantly exceeds the global average of 6.3%, indicating accelerated adoption and investment in veterinary pharmaceutical solutions.

Rising Pet Ownership Trends :

Increasing pet ownership across South Korea is driving demand for companion animal pharmaceuticals, creating new revenue streams for veterinary pharmaceutical manufacturers and distributors.

Livestock Disease Management :

Growing investments in livestock disease prevention and management are strengthening the market for animal health products, supported by South Korea's advanced agricultural infrastructure.

South Korea Veterinary Pharmaceuticals Market Dynamics

  • The country's advanced healthcare infrastructure and high disposable income levels support premium veterinary pharmaceutical adoption.
  • Regulatory frameworks promoting animal welfare and disease prevention further accelerate market expansion.
  • Domestic pharmaceutical manufacturers are increasingly investing in R&D to develop innovative solutions tailored to South Korean market needs, enhancing competitive positioning and market penetration across companion and production animal segments..

Related Ecosystem

Animal Health

Top Technologies
  • Polymerase Chain Reaction (PCR) Tests
  • Porcine
  • Immunodiagnostics
  • Lateral Flow Assays
  • Microarrays
Top Companies
  • Zoetis Inc.
  • Patterson Companies, Inc.
  • Virbac
  • Elanco Animal Health Incorporated
  • BOEHRINGER INGELHEIM GMBH

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Merck KGaA
    • Thermo Fisher Scientific Inc.
    • SANOFI
    • NOVARTIS
    • Pfizer Inc.

      Key Takeaways

      • South Korea's veterinary pharmaceuticals market will grow from USD 314.6M (2026) to USD 444.1M (2031) at a 7.1% CAGR.
      • South Korea's advanced regulatory environment and high pet ownership rates drive above-global-average market expansion.
      • South Korea's aquaculture and poultry sectors represent major growth opportunities for livestock pharmaceutical products.
      • South Korea's focus on preventive care and biosecurity standards will accelerate adoption of innovative veterinary solutions through 2031.

      Veterinary Pharmaceuticals Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment ONLINE PHARMACIES/E-COMMERCE (Distribution Channel)
      Forecast Period 2026–2031
      Growth Rate CAGR of 6.3% from 2026 to 2031
      Largest Segment COMPANION ANIMALS (Animal Type)
      Market Size Base Year (Billions) ~USD 29.01 (2026)
      Revenue Forecast (Billions) ~USD 39.37 (2031)
      Segments Covered Product Type, Type, Route Of Administration, Formulation Type, Indication, Animal Type, Distribution Channel, End User

      South Korea Veterinary Pharmaceuticals Market Report Segmentation

      8 segment dimensions are covered across the global market.

      By Product Type

      • Drugs
      • Immunomodulators
      • Medicated Feed Additives
      • Monoclonal Antibodies

      By Type

      • Amino Acids
      • Anti-Bacterial Drugs
      • Anti-Cancer Drugs
      • Anti-Fungal Drugs
      • Anti-Inflammatory Drugs
      • Anti-Parasitic Drugs
      • Anti-Viral Drugs
      • Cardiovascular & Renal Drugs
      • Cardiovascular And Renal Drugs
      • Cats
      • Cattle
      • Dogs
      • Enzymes
      • Gastrointestinal Drugs
      • Horses
      • Minerals And Vitamins
      • Other Companion Animals
      • Other Drugs
      • Other Livestock Animals
      • Other Medical Feed Additives
      • Other Medicated Feed Additives
      • Poultry
      • Swine

      By Route Of Administration

      • Oral
      • Other Routes Of Administration
      • Parenteral
      • Topical

      By Formulation Type

      • Aerosol/Spray
      • Liquid
      • Premix Formulations
      • Semi-Solid
      • Solid

      By Indication

      • Cardiovascular And Renal Diseases
      • Dermatological Diseases
      • Gastrointestinal Diseases
      • Infectious Diseases
      • Other Diseases
      • Pain Management

      By Animal Type

      • Companion Animals
      • Livestock Animals

      By Distribution Channel

      • Direct Sales
      • Online Pharmacies/
      • Online Pharmacies/E-Commerce
      • Retail Pharmacies
      • Veterinary Hospital Pharmacies

      By End User

      • Home Care Settings
      • Livestock Farms
      • Other End Users
      • Veterinary Hospitals & Clinics

      Target Audience

      • Pharmaceutical Manufacturers : Manufacturers need South Korea market intelligence to develop localized product portfolios, establish manufacturing partnerships, and capitalize on the 7.1% CAGR growth opportunity in this premium market.
      • Veterinary Distributors & Retailers : Distributors require detailed market segmentation and demand forecasts for South Korea to optimize inventory management, negotiate supplier contracts, and expand their veterinary pharmaceutical product offerings.
      • Investment & Private Equity Firms : Investors need comprehensive South Korea market data to evaluate acquisition targets, assess growth potential, and make informed decisions on veterinary pharmaceutical sector investments in Asia.
      • Veterinary Clinics & Hospitals : Veterinary practitioners need market insights on emerging pharmaceutical trends, new product launches, and treatment protocols specific to South Korea's companion and livestock animal populations.
      • Government & Regulatory Bodies : Policymakers and regulatory agencies require market analysis to develop evidence-based animal health policies, disease prevention strategies, and pharmaceutical approval frameworks for South Korea.

      Key Companies in the South Korea Veterinary Pharmaceuticals Market

      CompanyHQOwnershipStrongest segments
      ZOETIS INC.United StatesPublic CompanyCompanion animal therapeutics (parasiticides, dermatology, pain, other pharma),Livestock pharmaceuticals (vaccines, anti-infectives, other pharma),Diagnostics (point-of-care, instruments, reagents, reference labs),
      MERCK & CO., INCUnited StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Cardiovascular, pulmonary hypertension, and specialty (Winrevair, Adempas/Verquvo, Ohtuvayre, Prevymis, Bridion, Dificid, Zerbaxa),
      ELANCO ANIMAL HEALTH INCORPORATEDUnited StatesPublic CompanyCompanion animal parasiticides (Seresto, K-9 Advantage, Advantix, Advocate, Credelio Family, Interceptor Plus, Drontal family),Companion animal vaccines and therapeutics (including Galliprant and vaccines portfolio),Cattle products (Rumensin, Baytril, Experior and related medicated feed additives, injectables, vaccines),
      VIRBACFrancePublic CompanyCompanion animal therapeutics (vaccines, antibiotics, anti-inflammatories, dermatology, dental, specialty),Parasiticides (incl. collars like Prevexto),Farm animal vaccines (incl. Suigen Entero 3, PCV2, Donoban),
      CEVAUnited StatesPublic Company5G/5G-A baseband DSP and RAN IP (PentaG-RAN, XC20/XC21/XC23, Ceva-BX2),Connectivity IP (Ceva-Waves Bluetooth, Wi-Fi, UWB, Links, DragonFly NB-IoT),Sensing, audio, and spatial software IP (SensPro, BX1, ClearVox, RealSpace, MotionEngine),
      VETOQUINOLFrancePublic CompanyCompanion animal therapeutics (mobility, pain, dermatology, behavior, internal medicine, cardio-nephrology),Livestock therapeutics (udder health, antibiotics, reproduction, internal medicine),Antiparasitics (companion and livestock),
      DECHRA PHARMACEUTICALS PLCUnited KingdomPrivate CompanyCompanion animal therapeutics,Food-producing animal products,Equine therapies,
      HESTER BIOSCIENCES LIMITEDIndiaPublic CompanyPoultry vaccines,Large animal vaccines,Veterinary pharmaceuticals (therapeutics),
      ANIMALCARE GROUP PLCUnited KingdomPublic CompanyCompanion animal pharmaceuticals (pain, endocrine, chronic care),Dental and joint health (Orozyme, Plaqtiv+, Cosequin),Equine pharmaceuticals and supplements,

      ZOETIS INC.

      Zoetis Inc. is a United States-based public company founded in 2012 that employs 14,500 people. The company operates in the animal health sector.

      MERCK & CO., INC

      Merck & Co., Inc. is a United States-based public company founded in 1891 with 74,000 employees. The company is a major pharmaceutical and healthcare organization.

      ELANCO ANIMAL HEALTH INCORPORATED

      Elanco Animal Health Incorporated is a United States-based public company founded in 1954 with 9,650 employees. The company specializes in animal health products and services.

      VIRBAC

      Virbac is a French public company founded in 1968 with 6,442 employees. The company operates in the animal health and veterinary pharmaceutical sector.

      CEVA

      Ceva is a United States-based public company founded in 1999 with 400 employees. The company operates in the animal health industry.

      VETOQUINOL

      Vetoquinol is a French public company founded in 1933 with 2,454 employees. The company specializes in veterinary pharmaceuticals and animal health products.

      DECHRA PHARMACEUTICALS PLC

      Dechra Pharmaceuticals PLC is a United Kingdom-based private company founded in 1997 with 2,457 employees. The company operates in the veterinary pharmaceutical sector.

      HESTER BIOSCIENCES LIMITED

      Hester Biosciences Limited is an India-based public company founded in 1987. The company operates in the animal health and veterinary pharmaceutical sector.

      ANIMALCARE GROUP PLC

      Animalcare Group PLC is a United Kingdom-based public company with 220 employees. The company operates in the animal health and veterinary pharmaceutical industry.

      Reasons to Buy this Report

      • Market-Specific Growth Projections : Access detailed forecasts for South Korea's veterinary pharmaceutical market through 2031, enabling accurate business planning and investment decisions tailored to this high-growth Asian market.
      • Competitive Landscape Analysis : Understand South Korea's unique competitive dynamics, local manufacturer strategies, and market consolidation trends to identify partnership and acquisition opportunities in this advanced healthcare ecosystem.
      • Regulatory & Compliance Insights : Gain comprehensive knowledge of South Korean veterinary pharmaceutical regulations, approval processes, and compliance requirements essential for market entry and product commercialization.
      • Consumer Behavior & Demand Drivers : Analyze South Korea-specific pet ownership patterns, livestock management practices, and consumer spending behaviors to optimize product positioning and marketing strategies.
      • Segment Performance Breakdown : Evaluate performance across companion animal and production animal pharmaceuticals in South Korea, identifying high-potential therapeutic categories and distribution channels for targeted growth.

      Frequently asked questions

      What is the current size of South Korea's veterinary pharmaceuticals market?

      South Korea's veterinary pharmaceuticals market is valued at USD 314.6 million in 2026 and is projected to reach USD 444.1 million by 2031.

      What is the growth rate for South Korea's veterinary pharmaceuticals market?

      South Korea's veterinary pharmaceuticals market is growing at a CAGR of 7.1% from 2026 to 2031, which exceeds the global average of 6.3%.

      What sectors drive South Korea's veterinary pharmaceuticals demand?

      South Korea's companion animal, aquaculture, and poultry sectors are primary drivers, supported by rising pet ownership and intensive livestock production systems.

      How does South Korea's market compare to global trends?

      South Korea's 7.1% CAGR outpaces the global market CAGR of 6.3%, reflecting stronger domestic demand and regulatory support for animal health innovation.

      What regulatory factors influence South Korea's veterinary pharmaceuticals market?

      South Korea's stringent food safety standards, animal welfare regulations, and government biosecurity initiatives create favorable conditions for pharmaceutical adoption and innovation.

      RESEARCH METHODOLOGY

      This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

      Secondary Research

      This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the Veterinary Pharmaceuticals Market. It was also used to obtain important information about the key players, market classification, and segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the Veterinary Pharmaceuticals Markets. Primary sources from the demand side include healthcare professionals from hospitals, ambulatory surgical centers, long-term care facilities, diagnostic imaging centers, outpatient clinics, and other end users.

      A breakdown of the primary respondents is provided below:

      Veterinary Pharmaceuticals Market Size, and Share

      Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
      Note 2: Other Designations include sales managers, marketing managers, and product managers.
      Note 3: Tiers are defined based on a company’s total revenue as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The total size of the veterinary pharmaceuticals market was determined through data triangulation across three approaches, as outlined below. After each approach, the weighted average of the three was calculated based on the level of assumptions used in each.

      Veterinary Pharmaceuticals Market : Top-Down and Bottom-Up Approach

      Veterinary Pharmaceuticals Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed where applicable. The following figure shows the market validation, source structure, and data triangulation methodology implemented in the market engineering process.

      Market Definition

      The veterinary pharmaceuticals market comprises medicinal products used to prevent, control, and treat diseases in animals, excluding vaccines. It includes therapeutic drug classes such as anti-infectives (antibacterials, antivirals, antifungals, antiparasitic), anti-inflammatory drugs, hormonal therapies, dermatological drugs, cardiovascular drugs, gastrointestinal agents, and other prescription and over-the-counter pharmaceuticals. These products address indications including infectious diseases, dermatological disorders, reproductive health, metabolic diseases, and pain management, among others. The market covers both companion and livestock animals and is supplied through veterinary hospitals, clinics, pharmacies, and animal health distribution channels globally.

      Key Stakeholders

      • Veterinary Pharmaceutical Manufacturers (Branded & Generic Drug Manufacturers)
      • Veterinary Generic Drug Manufacturers
      • Veterinary Compounding Pharmacies
      • Veterinary Contract Manufacturing Organizations (CMOs)
      • Active Pharmaceutical Ingredient (API) Suppliers for Animal Health
      • Veterinary Hospitals and Specialty Veterinary Clinics
      • General Veterinary Practitioners
      • Livestock Farm Owners and Commercial Farm Operators
      • Companion Animal Owners (Pet Owners)
      • Veterinary Group Purchasing Organizations (GPOs)
      • Animal Health Distributors and Wholesalers
      • Veterinary Pharmacy Chains (Retail & Online)
      • E-Pharmacy Platforms for Animal Medicines
      • Regulatory Authorities (e.g., FDA-CVM, EMA, CDSCO, VMD)
      • Animal Health Contract Research Organizations (CROs)
      • Academic and Veterinary Research Institutes
      • Animal Health Insurance Providers (Pet Insurance Companies)
      • Feedlot and Integrated Livestock Production Companies
      • Animal Welfare Organizations

      Report Objectives

      • To define, describe, and forecast the veterinary pharmaceuticals market, product type, route of administration, formulation type, indication, animal type, distribution channel, end user, and region
      • To provide detailed information about the key factors influencing market growth, such as drivers, restraints, opportunities, challenges, and industry trends
      • To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis,
      • patent analysis, impact of AI, trends/disruption impacting customers’ business in the market, and the impact of the 2025 US tariff on the market.
      • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall veterinary pharmaceuticals market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To strategically profile the key players in this market and comprehensively analyze their market shares and core competencies.
      • To strategically analyze the veterinary pharmaceuticals market in five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To track and analyze competitive developments such as product launches and approvals, acquisitions, partnerships, collaborations, and expansions in the veterinary pharmaceuticals market

      Available customizations:

      • Based on the given market data, MarketsandMarkets offers customizations tailored to your company’s specific needs. The following customization options are available for the report:

      Competitive Landscape Assesment

      • Market share analysis for the North America and Europe region, which provides market shares of the top 3–5 key players in the veterinary pharmaceuticals market
      • Competitive leadership mapping for established players in the US

      Regional Analysis

      • Further breakdown of the Rest of European veterinary pharmaceuticals market into Austria, Finland, the Netherlands, Switzerland, and others
      • Further breakdown of the Rest of Latin American veterinary pharmaceuticals market into Argentina, Colombia, Chile, and others

      Company Information

      • Detailed analysis and profiling of additional market players (up to 5)

       

      Get the Full Veterinary Pharmaceuticals Market Report

      Full forecast, segment splits, and company analysis for all Veterinary Pharmaceuticals Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status